A Phase 1B/2, Open-Label, Dose-Finding Study to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination with either Crizotinib or PF-06463922 in Patients with Advanced or Metastatic NSCLC
A Phase 1B/2, Open-Label, Dose-Finding Study to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination with either Crizotinib or PF-06463922 in Patients with Advanced or Metastatic NSCLC